Insider Selling: Paysign, Inc. (NASDAQ:PAYS) Insider Sells 120,000 Shares of Stock

Paysign, Inc. (NASDAQ:PAYS - Get Free Report) insider Topline Capital Management, Ll sold 120,000 shares of Paysign stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $3.24, for a total value of $388,800.00. Following the completion of the transaction, the insider now owns 5,336,146 shares of the company's stock, valued at approximately $17,289,113.04. This represents a 2.20 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Topline Capital Management, Ll also recently made the following trade(s):

• On Monday, December 30th, Topline Capital Management, Ll sold 227,084 shares of Paysign stock. The shares were sold at an average price of $3.07, for a total value of $697,147.88.
• On Friday, December 27th, Topline Capital Management, Ll sold 231,187 shares of Paysign stock. The stock was sold at an average price of $3.31, for a total value of $765,228.97.

Paysign Stock Down 5.5 %

Shares of NASDAQ PAYS traded down $0.18 during midday trading on Wednesday, hitting $3.07. The stock had a trading volume of 270,262 shares, compared to its average volume of 354,662. Paysign, Inc. has a 1 year low of $2.48 and a 1 year high of $5.59. The company has a market capitalization of $164.39 million, a PE ratio of 20.47 and a beta of 0.95. The stock has a 50 day simple moving average of $3.25 and a 200-day simple moving average of $3.94.

Paysign (NASDAQ:PAYS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The company had revenue of $15.26 million for the quarter, compared to analyst estimates of $14.96 million. During the same quarter last year, the firm posted $0.02 EPS. As a group, analysts expect that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PAYS has been the topic of a number of research analyst reports. Lake Street Capital assumed coverage on shares of Paysign in a report on Friday, December 20th. They issued a "buy" rating and a $6.00 price target for the company. Barrington Research reiterated an "outperform" rating and issued a $7.00 target price on shares of Paysign in a research report on Monday, November 4th.

Institutional Trading of Paysign

Several large investors have recently bought and sold shares of PAYS. Renaissance Technologies LLC lifted its stake in Paysign by 25.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company's stock worth $6,484,000 after purchasing an additional 301,000 shares in the last quarter. Royce & Associates LP acquired a new stake in shares of Paysign in the third quarter valued at approximately $814,000. Barclays PLC increased its holdings in shares of Paysign by 327.4% in the third quarter. Barclays PLC now owns 47,090 shares of the company's stock valued at $173,000 after purchasing an additional 36,071 shares during the last quarter. Rhumbline Advisers lifted its position in Paysign by 25.1% during the second quarter. Rhumbline Advisers now owns 35,835 shares of the company's stock worth $154,000 after buying an additional 7,190 shares in the last quarter. Finally, Joule Financial LLC acquired a new position in Paysign during the third quarter worth $1,478,000. Hedge funds and other institutional investors own 25.89% of the company's stock.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.